SCHEMBL14804187

SCHEMBL14804187

CC(C)(C)[Si](C)(C)OCCCOc1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.49
RAB9A P51151 4/20 0.49
MAPT P10636 4/20 0.49
NPC1 O15118 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
HPGD P15428 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
SLC2A1 P11166 1/20 0.47
KCNH2 Q12809 1/20 0.47
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
HTT P42858 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14804182 0.92 L3MBTL1 (0.51) L3MBTL1RAB9AMAPTNPC1TDP1
SCHEMBL4894524 0.81 CYP1A2 (0.56) TDP1CYP1A2CYP2C19CYP2C9SLC2A1
SCHEMBL30725918 0.81 GAA (0.53) MAPTHPGDSMN1; SMN2DRD2DRD4
SCHEMBL14804147 0.81 L3MBTL1 (0.56) L3MBTL1RAB9AMAPTNPC1TDP1
SCHEMBL8536947 0.78 TAAR1 (0.41) SLC2A1KCNH2
SCHEMBL16901976 0.77 NPC1 (0.44) RAB9AMAPTNPC1HPGDSMN1; SMN2
SCHEMBL29628726 0.77 MAPT (0.37) L3MBTL1MAPTTDP1CYP1A2CYP2C19
SCHEMBL28580980 0.76 ALDH1A1 (0.57) L3MBTL1RAB9AMAPTNPC1TDP1
SCHEMBL4894370 0.76 NPC1 (0.60) L3MBTL1RAB9AMAPTNPC1TDP1
SCHEMBL12377707 0.76 NQO2 (0.49) L3MBTL1RAB9AMAPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 L3MBTL1 1136/4885RAB9A 2257/4885MAPT 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.